NOMIZO, T.; YAMAMOTO, H.; MURAYAMA, T.; FUKATA, H.; NAKAMURA, Y.; SONOMURA, M.; OKUNO, A.; KANDA, N.; WATANABE, C.; KITA, H. Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer. Trends in Immunotherapy, [S. l.], v. 6, n. 1, 2022. DOI: 10.24294/ti.v6.i1.1386. Disponível em: https://ojs.ukscip.com/index.php/ti/article/view/425. Acesso em: 6 apr. 2025.